Try our Advanced Search for more refined results

August 21, 2020

Intercept Pharmaceuticals, Inc. et al v. Apotex Inc. et al

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. February 27, 2023

    Generics Makers Settle Liver Drug Patent Fight On Eve Of Trial

    Intercept Pharmaceuticals, MSN Pharmaceuticals and Apotex told a Delaware federal judge that they've cut deals to end Intercept's claims that Apotex's proposed generic version of Ocaliva, treatment for a rare liver disease, infringes its patents, resolving the consolidated litigation just as the parties were to face off in a bench trial on Monday.

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login